Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether zoledronate changes number of participants who withdrew due to adverse events… compared with pamidronate or risedronate (very low certainty).
Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).